Biochemical markers of glucocerebrosidase (GCase) deficiency in primary macrophages derived from GBA1 mutation carriers with and without Parkinson’s disease
Objective: The aim of the present study was to assess biochemical markers in primary macrophages that could distinguish patient with Parkinson’s disease linked to mutations…Blood Lipid Biomarkers in Early Parkinson Disease and Parkinson Disease with Mild Cognitive Impairment
Objective: This study aims to investigate the association between comprehensive blood lipid biomarkers and Parkinson's disease (PD). Background: Studies have shown that the serum levels…The potential role of Per- and Polyfluoroalkyl Substances (PFAS) in movement disorders: Implications and Risk assessment to Human Health
Objective: The objective of our study is to critically summarized the neurotoxicity of Perfluoroalkyl substances (PFAS) and linked this environmental pollutant with movement disorders and…A brainstem-oriented PET/NMR method in Parkinson’s disease
Objective: To create a voxel-based method, oriented to the brainstem and allowing the detection of Parkinson’s disease (PD) and the study of the altered connectivity…A novel alpha-synuclein gene (SNCA) missense variant in an Austrian familiy with atypical neuropathological features
Objective: To offer clinical, genetic and neuropathological information in a novel alpha-synuclein gene (SNCA) missense variant to further our understanding of synucleinopathies. Background: Around 5–10% of…PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.
Objective: The present study has been focused to identify the molecular targets that involved in Cadmium-induced motor dysfunctions. At the same time, we also focused…Role of resting-state fMRI-based brain network modularity in differentiating SCA1 and SCA2
Objective: To ascertain the role of resting-state functional MRI (rsfMRI)-based modularity in differentiating spinocerebellar ataxia type 1 (SCA1) and spinocerebellar ataxia type 2 (SCA2). Background:…Covid vaccine induced parkinsonism and cognitive dysfunction
Objective: To describe movement disorder and cognitive impairment in two patients following COVID-19 vaccination. Background: The manifestation of neurological complications have been increasingly evidenced following…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…The Hidden Disease Burden and Treatment Experience of Patients with Essential Tremor: A Retrospective US Claims Analysis
Objective: To describe the attributes of patients with essential tremor (ET), associated comorbidities, and ET treatments using a US claims database. Background: ET is estimated…
- « Previous Page
- 1
- …
- 386
- 387
- 388
- 389
- 390
- …
- 1554
- Next Page »